These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15122272)

  • 1. Cautious exuberance after the first quarter.
    Howard K
    Nat Biotechnol; 2004 May; 22(5):491-2. PubMed ID: 15122272
    [No Abstract]   [Full Text] [Related]  

  • 2. Will investors return to biotechnology?
    Dorey E
    Nat Biotechnol; 1999 Feb; 17(2):128. PubMed ID: 10052340
    [No Abstract]   [Full Text] [Related]  

  • 3. Public biotechnology 2001--the numbers.
    Lähteenmäki R; Fletcher L
    Nat Biotechnol; 2002 Jun; 20(6):551-5. PubMed ID: 12042853
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotechnology. Bubble, bubble, toil and trouble.
    Boorstin J
    Fortune; 2001 Jun; 143(12):48. PubMed ID: 11409107
    [No Abstract]   [Full Text] [Related]  

  • 5. The rise of venture capital and biotechnology in the US and Europe.
    Lee DP; Dibner MD
    Nat Biotechnol; 2005 Jun; 23(6):672-6. PubMed ID: 15940233
    [No Abstract]   [Full Text] [Related]  

  • 6. Investors remain wary after first quarter downturn.
    Fletcher L
    Nat Biotechnol; 2002 May; 20(5):413-4. PubMed ID: 11981536
    [No Abstract]   [Full Text] [Related]  

  • 7. Public biotechnology 2002--the numbers.
    Lähteenmäki R; DeFrancesco L
    Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
    [No Abstract]   [Full Text] [Related]  

  • 8. When less is more.
    Booth BL
    Nat Biotechnol; 2007 Aug; 25(8):853-7. PubMed ID: 17687357
    [No Abstract]   [Full Text] [Related]  

  • 9. Beware the biotech barker.
    Jacobs T
    Nat Biotechnol; 2005 May; 23(5):538. PubMed ID: 15877065
    [No Abstract]   [Full Text] [Related]  

  • 10. Paying over the odds.
    Jacobs T
    Nat Biotechnol; 2006 Jan; 24(1):29. PubMed ID: 16404388
    [No Abstract]   [Full Text] [Related]  

  • 11. The protection racket.
    Jacobs T
    Nat Biotechnol; 2006 Sep; 24(9):1081. PubMed ID: 16964213
    [No Abstract]   [Full Text] [Related]  

  • 12. Diversa restructures, raising question over bioprospecting.
    Sheridan C
    Nat Biotechnol; 2006 Mar; 24(3):229. PubMed ID: 16525364
    [No Abstract]   [Full Text] [Related]  

  • 13. White biotechnology: ready to partner and invest in.
    Kircher M
    Biotechnol J; 2006; 1(7-8):787-94. PubMed ID: 16897821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public biotechnology 2005--the numbers.
    Lähteenmäki R; Lawrence S
    Nat Biotechnol; 2006 Jun; 24(6):625-34. PubMed ID: 16763588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotechnology overview: where the industry is heading.
    Rothman E
    Healthspan; 1987 Oct; 4(9):19-24. PubMed ID: 10284965
    [No Abstract]   [Full Text] [Related]  

  • 16. Public biotechnology 2004--the numbers.
    Lähteenmäki R; Lawrence S
    Nat Biotechnol; 2005 Jun; 23(6):663-71. PubMed ID: 15940232
    [No Abstract]   [Full Text] [Related]  

  • 17. Keeping your head when all about you are losing theirs.
    Jacobs T
    Nat Biotechnol; 2005 Jun; 23(6):662. PubMed ID: 15940231
    [No Abstract]   [Full Text] [Related]  

  • 18. European biotechnology firms approve of stock market mergers.
    Michael A
    Nat Biotechnol; 1998 Dec; 16(13):1301. PubMed ID: 9853595
    [No Abstract]   [Full Text] [Related]  

  • 19. Critics question direction of new investment group.
    Michael A
    Nat Biotechnol; 1999 Jun; 17(6):528-9. PubMed ID: 10385307
    [No Abstract]   [Full Text] [Related]  

  • 20. Celera: financial optimism, scientific skepticism.
    Dickson D
    Nat Med; 2000 Feb; 6(2):116. PubMed ID: 10655076
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.